Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Recurrence 2Gastrointestinal Stromal Tumors 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Sarcoma 1Neoplasms 1Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Glioblastoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × avapritinib × Clear all
NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

Blueprint Medicines Corporation

Phase 1 Completed
10 enrolled
CNSGastrointestinalSarcoma

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Blueprint Medicines Corporation

Phase 1 Completed
86 enrolled 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡